Company intelligence / Profile preview

Triveni Bio

Watertown, Massachusetts, United Statestriveni.bio ↗

Ownership: Private
Development stage: Other

Overview

Triveni Bio is advancing a pipeline of antibody-based therapies targeting immunological and inflammatory diseases. Lead program TRIV‑509 is a dual KLK5/7 inhibitor for atopic dermatitis with IND submission planned for Q1 2025. TRIV‑573 is a bispecific antibody combining KLK inhibition with IL‑13 targeting. A third program targets trypsin inhibition in hereditary pancreatitis. The company has raised significant venture capital to support progression into clinical trials[2][3].

Therapeutic areas: GastroenterologyDermatology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesFunctional antibodies[1][2][3]
Industry: Biotech

Drug pipeline

3 assets

TRIV-509

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Triveni Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triveni Bio.

Explore the full profile